Project: A novel inhibitor to prevent uncontrolled bleedings in anticoagulant users
| Acronym | DOAC-STOP (Reference Number: 10859) |
| Duration | 01/04/2017 |
| Project Topic | DOAC-STOP aims to develop PseudoXa, a biological for the instantaneous restoration of blood clotting activity in patients with major bleedings as a result of blood thinners. PseudoXa will be produced and the preclinical efficacy, pharmacokinetics (PK), and toxicity (TOX) of PseudoXa will be determined in vitro and in vivo. The end result will be a completed preclinical study dossier for PseudoXa. After the project, clinical phase development will be initiated. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 6 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | VarmX B.V. | Coordinator | Netherlands |
| 2 | Adlego Biomedical AB | Partner | Sweden |
| 3 | Northwick Park Institute for Medical Research | Partner | United Kingdom |
| 4 | Leiden University Medical Center | Partner | Netherlands |